Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Sees Significant Increase in Short Interest

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 1,457 shares, a growth of 762.1% from the April 30th total of 169 shares. Based on an average daily volume of 4,944 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.0% of the shares of the company are short sold.

Invesco Biotechnology & Genome ETF Price Performance

Shares of Invesco Biotechnology & Genome ETF stock opened at $83.80 on Friday. The company’s fifty day simple moving average is $80.32 and its 200-day simple moving average is $80.93. The stock has a market capitalization of $260.62 million, a PE ratio of 20.44 and a beta of 0.71. Invesco Biotechnology & Genome ETF has a 1-year low of $62.25 and a 1-year high of $85.73.

Institutional Trading of Invesco Biotechnology & Genome ETF

Institutional investors and hedge funds have recently modified their holdings of the company. Colonial Trust Advisors bought a new stake in shares of Invesco Biotechnology & Genome ETF during the 4th quarter valued at $25,000. Comerica Bank raised its position in shares of Invesco Biotechnology & Genome ETF by 86.2% during the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after purchasing an additional 175 shares during the period. Fifth Third Bancorp bought a new stake in Invesco Biotechnology & Genome ETF in the 1st quarter valued at $30,000. PNC Financial Services Group Inc. increased its holdings in Invesco Biotechnology & Genome ETF by 74.5% in the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after acquiring an additional 245 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in Invesco Biotechnology & Genome ETF by 63.2% in the 3rd quarter. NewEdge Advisors LLC now owns 883 shares of the company’s stock valued at $62,000 after acquiring an additional 342 shares during the last quarter.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.